Closed System– tag –
-
Automated iPSC Manufacturing Achieves Monoclonal Lines in Seven Weeks, Paving Way for Cost-Efficient Clinical Autologous Therapies
bioRxiv Unknown Overview A new study introduces a highly efficient, standardizable, and automatable workflow for generating monoclonal induced pluripotent stem cell (iPSC) lines from human skin biopsies, including comprehensive quality c... -
Global Summits Confront Cell & Gene Therapy Scale-Up: Automation, Cost Efficiency, and Mass Production Strategies
Informa Connect International Overview Upcoming international conferences, including Advanced Therapies Europe and the CAR-TCR Summit in September 2026, are set to address the urgent need for scalable and cost-effective manufacturing in ... -
Cell Therapy Consumables Market Set for $7.53 Billion Surge by 2032, Fueled by Automation and Closed Systems
Credence Research India Overview A new report from Credence Research projects the global cell therapy consumables market will reach $7.53 billion by 2032. This significant growth is primarily driven by the expanding adoption of advanced ... -
Pioneering Off-the-Shelf Immunotherapy: CellFiber and Tidewave Bio Partner on Scalable 3D Cell Culture Manufacturing
BioSpace Japan Overview CellFiber and Tidewave Bio have launched a collaborative research program to evaluate CellFiber's proprietary 3D cell encapsulation technology for scalable immune cell manufacturing. This proof-of-concept study, l... -
Jordan Advances Global CAR-T Access with High-Efficiency Point-of-Care Manufacturing Using CliniMACS Prodigy
ASCO Publications Jordan Overview In a significant step towards democratizing advanced cell therapies, point-of-care manufacturing of anti-CD19.1 CAR-T cells using the Miltenyi CliniMACS Prodigy system was successfully demonstrated in Jo... -
CAR-T’s Geography Problem: Manufacturing Bottlenecks Limit Access, Advances in Closed Systems and Bioprocessing are Key
pharmaphorum UK Overview CAR-T cell therapy's geographical accessibility is heavily dependent on its manufacturing process, with production costs, turnaround times, and available facilities directly impacting patient access. A critical b... -
Cell Therapy’s High Cost Rooted in Culture Flask Cytokine Strategy, Driving Shift to Quality over Quantity
Cell & Gene Therapy Review Global Overview A significant portion of cell therapy's cost problem originates in the culture flask, emphasizing the profound impact of cytokine strategy on cell quality and manufacturing economics. The focus ... -
CDMO Strategies Advance Next-Gen Biopharma: Automated Closed Systems Tackle Manufacturing Shortages
World Pharma Today Global Overview Contract Development and Manufacturing Organizations (CDMO) strategies are evolving towards end-to-end service models to support the surge in next-generation biopharmaceuticals, especially cell and gene... -
Europe’s Biotech Vanguard: Automated, Closed Systems Drive Next-Gen CGT Manufacturing and Decentralized Access
PharmTech.com ヨーロッパ Overview European biotechnology firms are pioneering next-generation manufacturing technologies for cell and gene therapies (CGT), centered on automated, closed systems. These innovations, exemplified by companie... -
Continuous Manufacturing and Automated Closed Systems Revolutionize Cell & Gene Therapy Production for Enhanced Efficiency and Quality
News-Medical.net UK Overview The commercial manufacturing of cell and gene therapies is being transformed by the imperative for continuous processing and automated closed systems to overcome current scalability and quality challenges. Th...
12